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Treat the patient, not the result
To the Editor: Several episodes of nursing and laboratory 
staff at a specialist tuberculosis (TB) hospital presenting 
with flu-like symptoms, who on further investigation were 
found to have acid-fast bacilli in their sputum yet normal 
chest radiographs, have occurred. In many instances, in the 
absence of other evidence of TB, these staff were not initiated 
on anti-TB treatment. Serial sputum investigations remained 
negative and the symptoms disappeared. Similarly, in the same 
institution there have been several reports of patients referred 
with a microbiological diagnosis of multi- or extensively 
drug-resistant tuberculosis. Owing to the protracted period 
of time needed to grow these organisms, the individuals 
concerned are commenced on first-line TB treatment. By the 
time the susceptibility results are received (usually several 
months later) and the patients referred to the specialist TB 
hospital for further management, both clinical and radiological 
improvement in response to first-line TB treatment has taken 
place, which suggests that there might have been some contact 
with TB (drug-susceptible or resistant), and the bacillus could 
have infected and behaved as a commensal for a short period 
and not caused disease in the ‘carrier’. This scenario is more 
relevant today, with the prevalence of MDR and XDR TB. 
If a chest radiograph is reported as clear by an experienced 
reader, and the individual is asymptomatic, then the sputum 
test should be repeated, including culture and susceptibility 
testing, before embarking on therapy with potentially toxic 
second-line TB drugs. Health workers should be cognisant of 
these confounders and remember to treat the patient – and not 
laboratory reports or radiographs.
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(ARV-) Free State? The moratorium’s 
threat to patients’ adherence and the 
development of drug-resistant HIV
To the Editor: Despite early fears that people living with 
HIV (PLWHs) in Africa would not be able to adhere to 
antiretrovirals (ARVs),1,2 research has shown that the 
proportion of PLWHs reporting ≥95% adherence in sub-
Saharan Africa is higher than that in North America.3 However, 
maintaining adherence is complex, and several factors 
affect patient ability to access and adhere to ARVs: patient 
characteristics and context, ARV regimen, clinical situation and 
the patient/health staff relationship.4
In October 2008, the new Minister of Health announced 
that 550 000 PLWHs – the highest number in the world – were 
on ARVs in South Africa.5 This achievement was recently 
tarnished by increasing alarm over Free State province’s public 
sector ARV programme. The Free State has the third-highest 
HIV prevalence (of 31%) in the country.6 Since December 2008, 
the province’s Department of Health stopped initiating new 
patients on ARVs7 because of out-of-stock drugs and lack of 
funds. An estimated 30 PLWHs are dying every day in the 
province while this hiatus continues.8 The moratorium will 
increase morbidity and mortality, but the loss of trust in the 
health system and the potential impact of the ARV crisis on 
existing patient adherence also need to be considered.
Campero et al. reported that patients already on ARVs share 
their medication with neighbours, relatives or friends who 
experience delays in receiving ARVs.9 This practice could 
lead to the development of drug resistance in people sharing 
medication if they consequently have differential exposure to 
ARVs,10-13 and raises serious public health concerns about drug 
failure, subsequent and more expensive drug regimens, and the 
spread of drug-resistant strains of HIV.
Patients’ perceptions of staff attitudes and waiting times 
were reported to be key factors for patients’ ARV adherence.14 
Conceivably, PLWHs will seek care in other provinces, and 
would consequently be required to return monthly to outlying 
clinics to pick up their ARVs. Transport costs and the time 
needed to reach clinics are risk factors to adherence and 
retention in care.15,16 Patients currently on treatment – in the 
Free State and elsewhere – are understandably anxious about 
the health system’s ability to guarantee lifelong access to ARVs.
An estimated 300 000 people might not have died of AIDS 
if the South African government had responded to the AIDS 
crisis quickly and in a coherent manner.17 How the government 
proceeds to contain and repair the damage being done in the 
Free State will be a litmus test for the long-term success of 
South Africa’s ARV programme.
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Are investigators satisfied with contract 
clinical research in South Africa?
To the Editor: In October 2008, I surveyed 75 principal 
investigators in South Africa with whom I had worked since 
2004. I emailed to each a covering letter, a survey sheet with 
tick boxes for answers to 13 questions, and a comment sheet. I 
received completed surveys from 35 investigators. I could find 
no similar surveys in the literature.
The respondents are experienced investigators, of whom 
66% had more than 5 years’ experience in clinical trials, and a 
further 24% 2 - 5 years’ experience; 37% had taken part in more 
than 5 trials in the previous 12 months, and a further 49% had 
taken part in 2 - 5 trials in the same period.
Investigator meetings were rated as ‘good’ by 51% of the 
investigators, and as ‘average’ by 43%; the supply of study 
materials to the site was rated as ‘good’ by 37% and ‘average’ 
by 57%. Most respondents felt that the general conduct of the 
study was ‘good’ (71%), with nobody rating the conduct as 
‘bad’. The conduct of monitors was rated as ‘good’ by 63% of 
investigators, with nobody rating them as ‘bad’.
Only 14% of investigators rated recruitment at their site as 
‘bad’, while 6% described the sponsor’s expectations of their 
site as ‘bad’. The process of closing a study at the site was rated 
as ‘good’ by 74%.
A preference for electronic case report forms was stated by 
59%, the rest preferring paper forms. Investigator fees were 
described as ‘good’ by 26% of investigators, and ‘average’ by 
57%.
Only 3% of investigators felt that the time to Medicines 
Control Council (MCC) approval was ‘good’, with 80% rating 
the time as ‘bad’.
Contract clinical research in South Africa has grown steadily 
in the last 5 years. This is the only survey that has been 
conducted to determine investigator satisfaction with the 
clinical trial industry. Investigators are generally satisfied with 
the process of conducting clinical research in South Africa, and 
are willing to utilise enhanced technology to stay abreast of the 
rest of the developing world in clinical trials. The time to MCC 
approval remains a concern but, with steps that are under way, 
I am certain that the dissatisfaction will change in the near 
future.
E Mitha
Newtown Clinical Research
Johannesburg
emitha@iburst.co.za
Kebble or quibble?
Dear Aunt Ethel,
To those skilled at matters surgical, a lost orchid is the 
euphemism for an ectopic testis or undescended testicle. Makes 
Tretchikoff’s originals/collectors’ pieces sound like priceless 
balderdash, perhaps?
Yours affectionately
Robert-Ian Caldwell
Hilton, KwaZulu-Natal
ric@caldwells.co.za   
